Sugi Predict

Sugi Predict / Compounds / SCHEMBL17065073

SCHEMBL17065073

SCHEMBL17065073

CON(C)C(=O)c1cc(C2CC2)cc([N+](=O)[O-])c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.43
▸ HPGD P15428 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ AHR P35869 1/20 0.39
▸ KMT2A Q03164 5/20 0.38
▸ HTT P42858 1/20 0.38
▸ PTPN2 P17706 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ PTPN6 P29350 1/20 0.37
▸ PTPN11 Q06124 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17073460 0.86 LMNA (0.39) ATMHPGDLMNAAHRKMT2A
SCHEMBL16238550 0.84 ATM (0.56) ATMHPGDKMT2AHTTGAA
SCHEMBL20632883 0.79 TSHR (0.50) ATMHPGDLMNAKMT2AHTT
SCHEMBL7235160 0.78 NPC1 (0.56) ATMHPGDLMNAKMT2AHTT
SCHEMBL17064462 0.78 MLYCD (0.35) —
SCHEMBL17064867 0.78 ATM (0.47) ATMHPGDLMNAKMT2AHTT
SCHEMBL17064571 0.78 ATM (0.47) ATMHPGDKMT2AHTTMEN1
SCHEMBL16961334 0.77 CYP3A4 (0.41) HPGDLMNAAHRKMT2AHTT
SCHEMBL29954895 0.76 ATM (0.45) ATMHPGDKMT2AHTTMEN1
SCHEMBL20632970 0.76 ATM (0.45) ATMHPGDLMNAKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
US-12162838-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-12-10 — — US disclosed
US-12116346-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-10-15 — — US disclosed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-20190322626-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2019-10-24 — — US disclosed
US-10329260-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2019-06-25 — — US disclosed
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-12-13 — — US disclosed
US-10125102-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2018-11-13 — — US disclosed
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-09-13 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
EP-3113772-A1 HUMAN PLASMA KALLIKREIN INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2017-01-11 — — EP disclosed
WO-2015134998-A1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2015-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 ATM 1332/4885HPGD 333/4885LMNA 1126/4885
US-12116346-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 ATM 2452/4885HPGD 432/4885LMNA 998/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 ATM 2452/4885HPGD 432/4885LMNA 998/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 ATM 2452/4885HPGD 432/4885LMNA 998/4885
US-10329260-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 ATM 1332/4885HPGD 333/4885LMNA 1126/4885
US-10125102-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 ATM 1332/4885HPGD 333/4885LMNA 1126/4885
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 ATM 1332/4885HPGD 333/4885LMNA 1126/4885
US-20190322626-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 ATM 1332/4885HPGD 333/4885LMNA 1126/4885
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 ATM 2452/4885HPGD 432/4885LMNA 998/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 ATM 2452/4885HPGD 432/4885LMNA 998/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 ATM 1604/4885HPGD 390/4885LMNA 824/4885
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 ATM 1332/4885HPGD 333/4885LMNA 1126/4885
US-12162838-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 ATM 2452/4885HPGD 432/4885LMNA 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.